StockData
Lexicon Pharmaceuticals, Inc. logo

Lexicon Pharmaceuticals, Inc. (LXRX) stock

LXRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/3064% above fair value
$1.53−0.14 (-8.38%)

Close on Nov 20, 2026Market cap $680.78MP/E –Yield –

Lexicon Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Lexicon Pharmaceuticals's free cash flow for the twelve months ending Dec 31, 2025 was -$67.85M. For fiscal 2025 it was -$67.85M. The highest annual figure on record is $183.87M in fiscal 2015.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$67.85M–
FY2024Dec 31, 2024-$179.81M–
FY2023Dec 31, 2023-$162.37M–
FY2022Dec 31, 2022-$90.18M–
FY2021Dec 31, 2021-$88.24M–
FY2020Dec 31, 2020-$143.06M-225.8%
FY2019Dec 31, 2019$113.74M–
FY2018Dec 31, 2018-$148.70M–
FY2017Dec 31, 2017-$185.62M–
FY2016Dec 31, 2016-$175.86M-195.6%
FY2015Dec 31, 2015$183.87M–
FY2014Dec 31, 2014-$75.70M–
FY2013Dec 31, 2013-$92.80M–
FY2012Dec 31, 2012-$94.95M–
FY2011Dec 31, 2011-$89.14M–
FY2010Dec 31, 2010-$83.50M–
FY2009Dec 31, 2009-$89.39M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025-$17.23M–
Q3 FY2025Sep 30, 2025-$23.83M–
Q4 FY2024Dec 31, 2024-$21.97M–
Q3 FY2024Sep 30, 2024-$53.93M–
Q2 FY2024Jun 30, 2024-$48.79M–
Q1 FY2024Mar 31, 2024-$55.13M–
Q4 FY2023Dec 31, 2023-$50.55M–
Q3 FY2023Sep 30, 2023-$41.70M–
Q2 FY2023Jun 30, 2023-$38.26M–
Q1 FY2023Mar 31, 2023-$31.86M–
Q4 FY2022Dec 31, 2022-$22.82M–
Q3 FY2022Sep 30, 2022-$19.44M–
Q2 FY2022Jun 30, 2022-$24.42M–
Q1 FY2022Mar 31, 2022-$23.50M–
Q4 FY2021Dec 31, 2021-$22.85M–
Q3 FY2021Sep 30, 2021-$17.36M–
Q2 FY2021Jun 30, 2021-$22.83M–
Q1 FY2021Mar 31, 2021-$25.20M–
Q4 FY2020Dec 31, 2020-$34.29M–
Q3 FY2020Sep 30, 2020-$40.41M-121.2%
Q2 FY2020Jun 30, 2020-$46.30M–
Q1 FY2020Mar 31, 2020-$22.05M–
Q4 FY2019Dec 31, 2019-$24.37M–
Q3 FY2019Sep 30, 2019$190.70M–
Q2 FY2019Jun 30, 2019-$26.90M–
Q1 FY2019Mar 31, 2019-$25.69M–
Q4 FY2018Dec 31, 2018-$27.17M–
Q3 FY2018Sep 30, 2018-$22.18M–
Q2 FY2018Jun 30, 2018-$52.54M–
Q1 FY2018Mar 31, 2018-$46.82M–
Q4 FY2017Dec 31, 2017-$33.72M–
Q3 FY2017Sep 30, 2017-$34.02M–
Q2 FY2017Jun 30, 2017-$32.30M–
Q1 FY2017Mar 31, 2017-$85.59M–
Q4 FY2016Dec 31, 2016-$48.94M–
Q3 FY2016Sep 30, 2016-$35.24M–

More Lexicon Pharmaceuticals figures

See a number that looks wrong?